Bicara Therapeutics
BCAX
106 hedge funds and large institutions have $475M invested in Bicara Therapeutics in 2025 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 43 increasing their positions, 16 reducing their positions, and 19 closing their positions.
169% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 16
74% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 19
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
14% more funds holding
Funds holding: 93 → 106 (+13)
4.5% more ownership
Funds ownership: 89.32% → 93.82% (+4.5%)
25% less capital invested
Capital invested by funds: $634M → $475M (-$159M)
54% less call options, than puts
Call options by funds: $11K | Put options by funds: $24K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$26.6M |
| 2 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$23.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.9M |
| 4 |
BlackRock
New York
|
+$9.17M |
| 5 |
Millennium Management
New York
|
+$8.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$28.2M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$18.2M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$18M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$15.4M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.8M |
BCAX Hedge Fund Activity: Q2 2025 in Review
106 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Bicara Therapeutics (BCAX) for Q2 2025, worth a combined $475M — down 25% from $634M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new BCAX positions and 19 closed out — a net gain of 14 holders — while 43 added to existing stakes and 16 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $26.6M. The largest seller was Braidwell, exiting entirely with an estimated $28.2M sold.
- 106 institutional investors held Bicara Therapeutics (BCAX) as of Q2 2025, up from 93 in Q1 2025.
- Funds reported $475M of Bicara Therapeutics stock for Q2 2025, down 25% quarter-over-quarter.
- 33 funds opened new Bicara Therapeutics positions in Q2 2025 and 19 closed out, a net change of +14 holders.
- The largest Bicara Therapeutics buyer in Q2 2025 was Vestal Point Capital, an estimated $26.6M added.
- The largest Bicara Therapeutics seller in Q2 2025 was Braidwell, an estimated $28.2M sold.
Based on aggregated 13F filings for Q2 2025.